Drugs / CAR19
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06911710 | Nov 2024 → Feb 2026 overdue | T lymphoblastic leukemia/lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, aggressive B-cell non-Hodgkin lymphoma +1 | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03467256 | May 2018 → Oct 2020 | B-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR19 | “Here we develop an anti-CD19 CAR (CAR19) comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.” PMID 34893603 ↗ Dec 2021 |
| Known as | CAR19 T cells | “The CAR19 T-cells is used to treat patients with relapsed/refractory pediatric B-cell Acute Lymphocytic Leukemia (ALL; n = 31) or adult B-cell Lymphoma (NHL; n = 23) in two...” PMID 34893603 ↗ Dec 2021 |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies.” PMID 34893603 ↗ Dec 2021 |
| Route | Intravenous | “Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.” NCT03467256 ↗ |
| Target | CD19 | “Chimeric antigen receptor (CAR) T cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies.” PMID 34893603 ↗ Dec 2021 |